Loading
KN026 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.
KN026 is a monoclonal antibody developed by Shanghai JMT-Bio and CSPC Megalith Biopharmaceutical. Its target is HER2. ClinicalTrials.gov describes the intervention as: KN026 is an antibody targeting HER2, administered via intravenous infusion. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07441460 (A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer) and NCT06747338 (A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer), in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07441460, plans to enrol 1800 participants with primary completion expected 2034-08-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Monoclonal antibody directed at HER2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to HER2.
1.KN026 binds HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"KN026" OR ABSTRACT:"KN026") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KN026, not a curated reading list.
Shares A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer, A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer, CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag pipeline.
Shares A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer, CSPC Pharmaceutical Group, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.